AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6752558 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: 6‐MP (50 mg/m2) p.o. daily + MTX (20‐30 mg/m2) p.o. weekly
Number of subjects: 58
Study 6752558 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B: 6‐MP (50 mg/m2) p.o. daily + MTX (75‐150 mg/m2) i.v. every two weeks
Number of subjects: 58
Study 6752558 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C: 6‐MP (50 mg/m2) p.o. daily + alternating 8‐week-courses of four biweekly i.v. injections of MTX (75‐150 mg/m2) and four biweekly i.v. injections of Cyclo (600 mg/m2)
Number of subjects: 58
Study 31796073 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Neratinib + Paclitaxel
Number of subjects: 100
Study 31796073 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 100
Study 31796073 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 100
Study 31796073 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib-based therapy
Number of subjects: 100
Study 31796073 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-gene signature
Number of subjects: 100
Study 31796073 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR3A-158V/F genotype
Number of subjects: 100
Study 27194364 — intervention group
Group type: EXPERIMENTAL
Intervention: CM (native collagen membranes)
Number of subjects: 19
Study 27194364 — intervention group
Group type: COMPARATOR
Intervention: VN (cross-linked collagen membranes)
Number of subjects: 19
Study 27194364 — intervention group
Group type: EXPERIMENTAL
Intervention: CM and VN groups
Number of subjects: 19
Study 26027861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml 0.8% Hyaluronic Acid (HA) applied immediately after surgery
Number of subjects: 40
Study 26027861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment applied)
Number of subjects: 40
Study 25030475 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult auditory distraction
Number of subjects: 34
Study 25030475 — intervention group
Group type: COMPARATOR
Intervention: Control (silent)
Number of subjects: 34
Study 25030475 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli responses
Number of subjects: 34
Study 25030475 — intervention group
Group type: EXPERIMENTAL
Intervention: Error rate correlation
Number of subjects: 34
Study 23044704 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 1000 shots at maximal tolerable intensity
Number of subjects: 36
Study 23044704 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroid (CS) injection
Number of subjects: 36
Study 22169787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubella vaccination (R-vac)
Number of subjects: 1329
Study 22169787 — intervention group
Group type: COMPARATOR
Intervention: Pre-vaccination status
Number of subjects: 1329
Study 19851160 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 89
Study 19851160 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 89
Study 19851160 — intervention group
Group type: COMPARATOR
Intervention: Typical care control
Number of subjects: 89
Study 19851160 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection phase
Number of subjects: 89
Study 19851160 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjection phase
Number of subjects: 89
Study 17069488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 685-nm wavelength, output power of 50 mW, energy density of 4 J/cm².
Number of subjects: 20
Study 17069488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser irradiation).
Number of subjects: 20
Study 15129420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195
Study 15129420 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 195
Study 12790985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled mucosectomy
Number of subjects: 35
Study 12790985 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 35
Study 11783265 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture
Number of subjects: 64
Study 11783265 — intervention group
Group type: COMPARATOR
Intervention: Control (mannitol and furosemide)
Number of subjects: 64
Study 7928125 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-specific education program
Number of subjects: 182
Study 2528969 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine 600 mg/day for 18 weeks
Number of subjects: 74
Study 2528969 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine 900 mg/day for 9 weeks
Number of subjects: 74
Study 2528969 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine 1200 mg/day for 9 weeks
Number of subjects: 74
Study 2528969 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine 1200 mg/day or highest tolerated dose at 8-hourly intervals after washout
Number of subjects: 74
Study 2528969 — intervention group
Group type: COMPARATOR
Intervention: zidovudine 600 mg/day
Number of subjects: 74
Study 2528969 — intervention group
Group type: COMPARATOR
Intervention: zidovudine 900 mg/day
Number of subjects: 74
Study 2528969 — intervention group
Group type: COMPARATOR
Intervention: zidovudine 1200 mg/day
Number of subjects: 74
Study 2528969 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine
Number of subjects: 74
Study 1252882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole 2 tablets twice daily
Number of subjects: 100
Study 1252882 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 1 g twice daily
Number of subjects: 100
Study 30947708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking While Moving in English (TWM-E) program
Number of subjects: 10
Study 30947708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study 27982478 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-increased risk of T2D
Number of subjects: 34840
Study 27982478 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-increased fasting glucose
Number of subjects: 34840
Study 27982478 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D and fasting glucose effects on lumbar spine BMD
Number of subjects: 34840
Study 25263498 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ampicillin and metronidazole
Number of subjects: 176
Study 25263498 — intervention group
Group type: COMPARATOR
Intervention: Multiple-day regimen of ampicillin/amoxicillin and metronidazole
Number of subjects: 176
Study 23337557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi/yoga
Number of subjects: 92
Study 22072853 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Dimethicone plus water (up to 100 mL)
Number of subjects: 148
Study 22072853 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus water (up to 100 mL)
Number of subjects: 148
Study 22072853 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Dimethicone and NAC plus water (up to 100 mL)
Number of subjects: 148
Study 22072853 — intervention group
Group type: COMPARATOR
Intervention: Water alone (100 mL)
Number of subjects: 148
Study 19153339 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin, 0.1%, applied twice daily to the face and ears
Number of subjects: 1131
Study 19153339 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream, applied twice daily to the face and ears
Number of subjects: 1131
Study 17005814 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 400/200/600
Number of subjects: 71
Study 17005814 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 300/200/600
Number of subjects: 71
Study 17005814 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 300/100
Number of subjects: 71
Study 17005814 — intervention group
Group type: COMPARATOR
Intervention: RIF 600 alone
Number of subjects: 71
Study 17005814 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV/RIF 300/200/600 and ATV/RTV/RIF 400/200/600
Number of subjects: 71
Study 17005814 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV with RIF
Number of subjects: 71
Study 12770652 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of nifedipine intranasally delivered
Number of subjects: 989
Study 12770652 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery postponed for BP control)
Number of subjects: 989
Study 11139975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned biphasic waveforms (based on an RC model with a time constant of 3.5 ms)
Number of subjects: 91
Study 11139975 — intervention group
Group type: COMPARATOR
Intervention: Standard biphasic waveforms (phase 1 set to 65% tilt and phase 2 = phase 1)
Number of subjects: 91
Study 9493669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Proportional Assist Ventilation (PAV)
Number of subjects: 42
Study 8886294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride 0.3 mg/kg intravenously
Number of subjects: 6
Study 8886294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2552868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone isonicotinate (four puffs bid for seven days, ie, 0.5 mg bid for seven days; last four puffs 30 minutes before TDI)
Number of subjects: 6
Study 2552868 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 6
Study 2552868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone isonicotinate
Number of subjects: 6
Study 4596620 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 24
Study 4596620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31739245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 μg·kg-1·min-1)
Number of subjects: 12
Study 31739245 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 12
Study 29261655 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cell salvage use
Number of subjects: 3028
Study 29261655 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care without routine salvage use
Number of subjects: 3028
Study 26255060 — intervention group
Group type: EXPERIMENTAL
Intervention: Air current directed at the face
Number of subjects: 10
Study 23408763 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL) group
Number of subjects: 48
Study 23408763 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RBP4 levels
Number of subjects: 48
Study 23408763 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone levels
Number of subjects: 48
Study 23408763 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG levels
Number of subjects: 48
Study 23408763 — intervention group
Group type: COMPARATOR
Intervention: Weight regain (WR) group
Number of subjects: 48
Study 21705157 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (3 mL)
Number of subjects: 34
Study 21705157 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection (3 mL)
Number of subjects: 34
Study 21705157 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (3 mL)
Number of subjects: 34
Study 19882878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial asthma (BA)
Number of subjects: 0
Study 19882878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 0
Study 19882878 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (DM1)
Number of subjects: 0
Study 16799446 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of school dental screening
Number of subjects: 0
Study 16799446 — intervention group
Group type: COMPARATOR
Intervention: Traditional model of school dental screening
Number of subjects: 0
Study 15245891 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc labelled microballoons (MB)
Number of subjects: 0
Study 15245891 — intervention group
Group type: COMPARATOR
Intervention: Nonfloating microspheres (NF) (control)
Number of subjects: 0
Study 10942162 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) at 5 pmol/min
Number of subjects: 19
Study 10942162 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) at 10 pmol/min
Number of subjects: 19
Study 10942162 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) at 20 pmol/min
Number of subjects: 19
Study 10942162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 19
Study 9311397 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood for 18 hours
Number of subjects: 120
Study 9311397 — intervention group
Group type: COMPARATOR
Intervention: Control group (received allogeneic red cells if hemoglobin < 5 mmol/L)
Number of subjects: 120
Study 9311397 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion group
Number of subjects: 120
Study 9311397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 9311397 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood
Number of subjects: 120
Study 8456428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of hirulog (0.6 mg kg-1 h-1 for 2 h)
Number of subjects: 54
Study 8456428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of hirulog
Number of subjects: 54
Study 8456428 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of hirulog
Number of subjects: 54
Study 8456428 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hirulog
Number of subjects: 54
Study 2994698 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20
Study 30297909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ipilimumab with nivolumab
Number of subjects: 23
Study 30297909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 23
Study 26924770 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies for metastatic renal cell carcinoma
Number of subjects: 5549
Study 26924770 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase NLR at Week 6 by 25-50%
Number of subjects: 5549
Study 26924770 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase NLR at Week 6 by > 75%
Number of subjects: 5549
Study 26924770 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease NLR at Week 6 by 25-50%
Number of subjects: 5549
Study 26924770 — intervention group
Group type: COMPARATOR
Intervention: No change in NLR (decrease < 25% to increase < 25%)
Number of subjects: 5549
Study 24809264 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (11-30 cmH2O)
Number of subjects: 120
Study 24809264 — intervention group
Group type: COMPARATOR
Intervention: Normal PEEP (3-10 cmH2O)
Number of subjects: 120
Study 22340541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (0.2 g/kg) and soybean oil (1.0 g/kg)
Number of subjects: 57
Study 22340541 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (1.2 g/kg)
Number of subjects: 57
Study 20590759 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD)
Number of subjects: 59
Study 20590759 — intervention group
Group type: COMPARATOR
Intervention: Internal endoscopic biliary drainage (internal EBD)
Number of subjects: 59
Study 18820784 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O during CPB
Number of subjects: 30
Study 18820784 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 30
Study 16279145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 64
Study 16279145 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 64
Study 12445220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype brush head N2.3 for the Philips Jordan Sensiflex 2000 PTB
Number of subjects: 137
Study 10348424 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking in patients with arteriosclerosis obliterans
Number of subjects: 23
Study 10348424 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking in normal subjects (control group)
Number of subjects: 23
Study 10348424 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with arrested blood circulation to a lower limb
Number of subjects: 23
Study 10348424 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed and duration
Number of subjects: 23
Study 10348424 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate during walking and recovery
Number of subjects: 23
Study 8745020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and trimethoprim-sulfamethoxazole
Number of subjects: 80
Study 8745020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1674231 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of roxatidine acetate at night
Number of subjects: 725
Study 1674231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 6223699 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (mean daily dose: 319 mg)
Number of subjects: 20
Study 6223699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (mean daily dose: 4,701 mg)
Number of subjects: 20
Study 6223699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31601180 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care gastric sonography
Number of subjects: 102
Study 28791977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 26
Study 28791977 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 26
Study 28791977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS)
Number of subjects: 26
Study 27629128 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant RT following radical hysterectomy (Group 1)
Number of subjects: 55
Study 27629128 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant RT following type 1 hysterectomy (Group 2)
Number of subjects: 55
Study 27629128 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary curative RT (Group 3)
Number of subjects: 55
Study 24329972 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cognitive behavioral therapy
Number of subjects: 402
Study 24329972 — intervention group
Group type: COMPARATOR
Intervention: Standard cessation treatment without extended cognitive behavioral therapy
Number of subjects: 402
Study 24329972 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nicotine replacement therapy
Number of subjects: 402
Study 22040514 — intervention group
Group type: EXPERIMENTAL
Intervention: Authority Acceptance scale from the Teacher Observation of Classroom Adaptation‐Revised (AA‐TOCA‐R)
Number of subjects: 8820
Study 22040514 — intervention group
Group type: EXPERIMENTAL
Intervention: Item scaling of the AA‐TOCA‐R
Number of subjects: 8820
Study 19688862 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV)
Number of subjects: 22
Study 19688862 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV)
Number of subjects: 22
Study 17403440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC)
Number of subjects: 1716
Study 15270789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (initially 30 mg QD, titrated to 45 mg)
Number of subjects: 200
Study 15270789 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (initially 1.75 mg QD, titrated to 10.5 mg)
Number of subjects: 200
Study 11172962 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10 x 3 Gy (total dose, 30 Gy) in 2 series (5 x 3Gy) separated by 8 weeks
Number of subjects: 129
Study 11172962 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 7 x 3 Gy (total dose, 21 Gy) in 1 series within 2 weeks
Number of subjects: 129
Study 11172962 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 129
Study 9543065 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF alone
Number of subjects: 115
Study 9543065 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 followed by GM-CSF
Number of subjects: 115
Study 8083702 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational therapies in adjuvant therapy RCTs (14 of 90 RCTs)
Number of subjects: 77488
Study 8083702 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational therapies in advanced-disease therapy RCTs (3 of 141 RCTs)
Number of subjects: 77488
Study 8083702 — intervention group
Group type: COMPARATOR
Intervention: Dose-intensity with blood-product support trials
Number of subjects: 77488
Study 8083702 — intervention group
Group type: COMPARATOR
Intervention: Locally advanced disease trials
Number of subjects: 77488
Study 3056259 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin for 24 weeks
Number of subjects: 0
Study 3056259 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin for 12 weeks followed by placebo for 12 weeks
Number of subjects: 0
Study 29124324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Fatigue (MF)
Number of subjects: 11
Study 29124324 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 11
Study 28082211 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppositories every 8 hours during phototherapy
Number of subjects: 79
Study 28082211 — intervention group
Group type: COMPARATOR
Intervention: No glycerin suppositories (sham group)
Number of subjects: 79
Study 28082211 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppositories
Number of subjects: 79
Study 26311445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring autograft
Number of subjects: 99
Study 26311445 — intervention group
Group type: COMPARATOR
Intervention: Tibialis posterior allograft
Number of subjects: 99
Study 26311445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (autograft and allograft)
Number of subjects: 99
Study 24263274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity patient simulator (HPS) training
Number of subjects: 19
Study 24263274 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 19
Study 21297190 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity aerobic (ATH; 80% VO₂peak)
Number of subjects: 30